Side-by-side · Research reference

ProstamaxvsRetatrutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED11/38 cited

BPhase 2HUMAN-REVIEWED10/41 cited

Prostamax

Khavinson Bioregulator · Tissue-Specific Peptide

0.05 ng/mLActive concentrationZakutskiĭ 2006

2.5×SCE frequency increaseDzhokhadze 2012

4 AAPeptide length

SQ · Protocol per Khavinson tradition

Retatrutide

Triple-receptor agonist · Phase 3

1–12 mgWeekly doseJastreboff 2023

24.2%Body-weight ↓Jastreboff 2023

~6 daysHalf-life (est)

SQ · Abdomen · Once weekly

01Mechanism of Action

Parameter

Prostamax

Retatrutide

Primary target

Chromatin in prostatic cells — pericentromeric heterochromatin regions

GLP-1R + GIPR + Glucagon receptor (triple agonism)Jastreboff 2023

Pathway

Epigenetic modulation → heterochromatin decondensation → transcriptional derepressionDzhokhadze 2012

Triple-receptor activation → ↑insulin (GLP-1+GIP), ↓gastric emptying, ↑lipid handling, ↑energy expenditure (glucagon component)Jastreboff 2023

Downstream effect

Increased sister chromatid exchange, Ag-NOR activation, reduced C-heterochromatin condensation; tissue-specific regenerative stimulation in prostate organotypic culturesDzhokhadze 2012 Zakutskiĭ 2006

Maximal weight loss across class. Glucagon component drives lipolysis and energy expenditure beyond GLP-1+GIP aloneJastreboff 2023

Feedback intact?

—

Origin

Synthetic tetrapeptide modeled on naturally occurring protein-derived bioregulators isolated between lysine-arginine motifs in long-lived speciesKhavinson 2017

Synthetic peptide engineered for balanced affinity at three incretin / glucagon receptorsJastreboff 2023

Antibody development

—

02Dosage Protocols

Parameter

Prostamax

Retatrutide

Effective concentration (in vitro)

0.05 ng/mLZakutskiĭ 2006

Organotypic culture model; demonstrated tissue-specific stimulation.

—

Human clinical dose

Not established

No published human trials; dosing extrapolated from Russian clinical tradition (not peer-reviewed).

—

Evidence basis

Animal / organotypic cultureZakutskiĭ 2006 Dzhokhadze 2012

No randomized controlled trials in humans.

Phase 2 trial; Phase 3 ongoingJastreboff 2023

Age groups studied

Young (3-week) and aged (18-month) rats; elderly humans (75–86 years) in vitroZakutskiĭ 2006 Dzhokhadze 2012

—

Duration

Not specified

Khavinson protocols typically 10–20 days per cycle; no long-term safety data.

Indefinite for chronic indication (presumed)

Standard dose

—

12 mg / week (max efficacy)Jastreboff 2023

Phase 2 trial dose. Phase 3 dosing TBD.

Frequency

—

Once weekly

Titration schedule

—

2 mg → 4 mg → 8 mg → 12 mg over 16 weeks

Reconstitution

—

Investigational; not commercially available

Timing

—

Any time of day

Half-life

—

~6 days (estimated from class)

04Side Effects & Safety

Parameter

Prostamax

Retatrutide

Published adverse events

None reported in available literature

—

Genotoxicity signals

Increased sister chromatid exchange (SCE) — marker of DNA recombination/repair; unclear long-term implications

—

Metal ion interactions

Modulates Cu(II) and Cd(II) chromatin effects; unknown clinical relevance

—

Human safety data

Absent — no published Phase 1/2/3 trials

—

GI symptoms

—

Nausea, vomiting, diarrhea (very common, dose-dependent)Jastreboff 2023

Heart rate

—

↑ resting HR (3–7 bpm at 12 mg)Jastreboff 2023

Glucose handling

—

Glycemic improvement; rare hyperglycemia from glucagon component

Pancreatitis risk

—

Class warning

Thyroid C-cell tumours

—

Class warning (presumed)

Pregnancy / OB

—

Avoid (insufficient data)

Absolute Contraindications

Prostamax

·Active prostate malignancy — epigenetic modulation effects unknown in cancer

Retatrutide

·MTC personal or family history (presumed class effect)
·Pregnancy / breastfeeding

Relative Contraindications

Prostamax

·History of prostate cancer — theoretical concern re: transcriptional activation
·Undiagnosed prostatic nodules or elevated PSA

Retatrutide

·Severe gastroparesis
·History of pancreatitis
·Severe cardiovascular disease (HR signal)

05Administration Protocol

Parameter

Prostamax

Retatrutide

1. Route

Subcutaneous or intramuscular — per Khavinson bioregulator tradition. No published human pharmacokinetic data.

Investigational peptide. Research vials reconstituted with bacteriostatic water per label.

2. Reconstitution

If lyophilised: reconstitute with sterile water per manufacturer protocol (not standardized in literature).

SQ — abdomen, thigh, or upper arm. Rotate weekly.

3. Frequency

Typically daily or every-other-day in Russian clinical tradition; duration 10–20 days per cycle.

Once weekly, same day.

4. Monitoring

No established biomarkers. Theoretical: PSA, prostate imaging, symptom scores (IPSS for BPH).

Refrigerate 2–8 °C. Light-protected.

5. Note

All protocols derived from non-peer-reviewed Russian clinical practice; Western regulatory approval absent.

27–31G, 4–8 mm insulin syringe.